Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Investigating Overuse of Antipsychotic Drugs in Dementia Patients

By Drug Discovery Trends Editor | April 13, 2015

The chance of a person with dementia receiving antipsychotic drugs in a nursing home is 1-in-3.Rutgers will take the lead in a three-year study that will investigate the effectiveness of federal and state initiatives to address overprescribing of antipsychotic medications for dementia patients in nursing homes.
 
Stephen Crystal, Board of Governors professor and associate director for Health Services Research at Rutgers’ Institute for Health, Health Care Policy and Aging Research, is the principal investigator for the study, “Improving Medication Safety in Nursing Home Dementia Care.” Crystal will work with regulators, patient advocates and other groups to track the progress of medication safety in each state.
 
The project’s goal is to identify strategies to reduce the number of dementia patients in nursing homes who are receiving antipsychotic medications.  
 
“Family members may not realize the kinds of medications their loved ones are receiving. Antipsychotic medications have a sedating effect that leads to inactivity and falls, and they have many serious risks,” says Crystal, a professor at the Rutgers School of Social Work. The overuse of antipsychotics in the elderly also can lead to physical inactivity, more time in bed and pneumonia due to inactivity.
 
Antipsychotic medications, approved to treat serious mental illnesses like schizophrenia and bipolar disorder, carry an FDA Black Box warning reserved for prescription drugs that pose significant risk of serious or life-threatening adverse effects. Antipsychotics are particularly dangerous for elderly patients with dementia and have been found to cause an increased risk of death among nursing home residents. 
 
The chance of a person with dementia receiving antipsychotic drugs in a nursing home is one in three, according to a March 2015 study by the Government Accountability Office. The study also found that 33 percent of those who had longer stays (over 100 days) were given a medication, compared with 23 percent of those who had shorter stays.
 
“The FDA has determined that there is a significant increase in the risk of death associated with these medications. While people with dementia may display behaviors, such as moaning and wandering and sometimes aggression, there is a high cost and health risk to managing these problems with antipsychotics,” says Crystal. 
Crystal says nursing home patients with dementia can benefit from a variety of interventions, from music therapy programs to warm relationships with staff members who interact with them. But too often, he says, dementia patients receive antipsychotics instead of interventions to help them communicate, engage them in activities and address their distress.
 
To find out a nursing home’s antipsychotic use rate, Crystal recommends visiting Nursing Home Compare on Medicare.gov. This site combines all of the quality measures of nursing homes as reported by Medicare. If a resident in a nursing home is being given antipsychotic medications, Crystal recommends that family members speak with staff about limiting the duration and dosage and review the overall plan of care with the medical director.
 
“You, as the family member, are providing informed consent for your loved one to receive this treatment. It is your right to know what the compelling need is for this medication. Ask what else they have tried and when another medical review of the plan of care will take place. You can be an advocate for your loved one,” Crystal says. 
 
Source: Rutgers University

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE